TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07037758: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

Sponsor: Amgen · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 380 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07037758 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07037758 Rescue Dossier →